San Francisco / Seattle / Atlanta / Tyrol / Los Angeles / Detroit / Ingelheim / Oakland / /
Company
Aventis / Amgen / Medicaid Services / Puget / Dendreon / Pfizer / Geschwind SA / Sanofi / America Project From / Unicon Research Corp. / /
Continent
America / /
Country
Puerto Rico / Austria / United States / North America / /
Currency
USD / / /
Facility
National Cancer Institute / National Hospital / University of Southern California / University of California-San Francisco / / /
IndustryTerm
treatment for nonmetastatic prostate cancer / care for men newly diagnosed with prostate cancer / treatment of prostate cancer / co-insurance/co-payments / care of patients with prostate cancer / prostate cancer treatment / therapy for localized disease / prostate cancer care / /
MedicalCondition
local/regional disease / Urologic Diseases / advanced disease / DF / urological disease / common disease / common solid cancer / CONCLUSIONS Prostate cancer / early prostate cancer / prostate / prostatic neoplasms / common solid tumor / inpatient prostate cancer / prostate cancer / MS / DISCUSSION Prostate cancer / nonmetastatic prostate cancer / tumor / cancer / distant disease / disease / Ovary cancer / localized disease / localized prostate cancer / comorbid diseases / earlier stage disease / /
MedicalTreatment
chemotherapy / radiotherapy / Surgery / prostatectomy / drug therapy / /
NaturalFeature
Tyrol / /
Organization
National Cancer Institute / NAMCS / Division of Prevention / Keck School of Medicine / National Hospital / University of Southern California / Los Angeles / Department of Urology / Medicare / University of California-San Francisco / San Francisco / American Cancer Society / /
Person
David F. Penson / Rate Av Annualized Rate / / /
Position
physician / Hospital outpt Physician / general public health burden / /
ProvinceOrState
King County / Southern California / Hawaii / Connecticut / Washington / Utah / California / Iowa / /